We are international
• treatment options TEXT SIZE   
Novel Therapies


Kyprolis® (carfilzomib) is a next-generation proteasome inhibitor. Kyprolis is FDA-approved for the treatment of patients with multiple myeloma (MM) who have received at least two prior therapies, including bortezomib and an immunomodulatory agent (IMiD), and have demonstrated disease progression on or within 60 days of the completion of the last therapy.

General Information
Clinical Trials
Blogs and Press Releases
Kyprolis®; for Injection Tip Card
Onyx Pharmaceuticals 360™ (Onyx 360)
Onyx 360 is a comprehensive patient and caregiver support and services program designed to help patients navigate the treatment journey, including reimbursement and payment support, treatment support and referrals to third-party organizations for day-to-day and emotional support.

Understanding Kyprolis®; (carfilzomib) for Injection
This booklet discusses Kyprolis, the results of clinical trials with Kyprolis, how and when it is administered, its possible side effects, and how to manage them.